Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
Andrew H. Sims(Western General Hospital), Simon P. Langdon(Edinburgh Cancer Research)
Cited by 49
Related Papers
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
|BMC Cancer|2018|107
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of<i>in vitro</i>breast cancer models
|Oncotarget|2015|96
HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
|Breast Cancer Research|2019|69
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
|Molecular Cancer Therapeutics|2007|55
Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function
|Cell Death and Differentiation|2021|49